Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
Study Details
Study Description
Brief Summary
The goal of this clinical research study is to compare chemotherapy given with rituximab to chemotherapy followed by rituximab. The safety of both treatment schedules will be studied. Laboratory tests of genetic changes in blood and bone marrow before and during the study will also be monitored.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 3 |
Detailed Description
Rituximab is a monoclonal antibody that is designed to attach to leukemia cells and activate a series of events that may cause the cancer cells to die.
Fludarabine is designed to make cancer cells less able to repair damaged DNA (the genetic material of cells). This may increase the likelihood of the cells dying.
Mitoxantrone is designed to stop cancer cells from making DNA, which may stop the cells from making more cells.
Dexamethasone is a corticosteroid that is similar to a natural hormone made by your body. Dexamethasone is often given to MM patients in combination with other chemotherapy to treat cancer.
Study Groups:
If you are found eligible to take part in this study, you will be randomly assigned (as in the flip of a coin) to 1 of 2 study groups. Each group will receive 8 "cycles" of treatment. One (1) cycle will last 28 days.
Group 1:
If you are in Group 1, you will receive the following drugs at the following times. Each study cycle is 28 days:
-
Rituximab will be given through a needle in the vein over about 90 minutes on Days 1 and 8 of the first course Cycle 1, and on Day 1 only of Cycles 2-5 of Fludarabine/ Mitoxantrone/ Dexamethasone (FND) treatment.
-
Fludarabine will be given through a needle in the vein over about 15 minutes on Days 2-4 of each cycle.
-
Mitoxantrone will be given through a needle in the vein over about 15 minutes on Day 2 of each cycle.
-
You will take dexamethasone by mouth with water on Days 1-5 of each 28-day cycle (FND).
If you miss any doses of the study drugs, please contact the research staff for instructions.
You will not receive rituximab in Cycles 6-8. When the 8 cycles are finished, you will begin receiving the drug interferon on Days 1-14 each month for 1 year. Dexamethasone will be given on Days 1-3 every month for 1 year.
Patients in group 2 will receive fludarabine on Days 1-3, mitoxantrone on Day 1, and dexamethasone on Days 1-5 of each 28-day cycle. When 8 cycles of treatment are finished, patients will begin receiving the drug interferon on Days 1-14 each month for 1 year. Dexamethasone will be given on Days 1-3 every month for 1 year. About 4 months after interferon treatment starts, patients in group 2 will begin receiving rituximab once a month for 6 months.
Other drugs may be given to help decrease the risk of or ease side effects. Treatment may be delayed or stopped if side effects are severe.
Most of the drugs are given by vein. A catheter (a tube) will be placed in a vein to decrease the number of needle sticks. Dexamethasone may be taken by mouth instead of given by vein.
Some patients in this study, with changes in certain genes will receive different chemotherapy drugs than other patients in the study will. The patients will, like all the other patients, receive rituximab and interferon. But instead of the FND chemotherapy regimen, they will receive a sequence of three regimens, CHOD-Bleo, ESHAP, and NOPP. The drugs in these regimens include: cyclophosphamide, doxorubicin, vincristine, bleomycin, VP-16, Ara-C, cisplatin, mitoxantrone, procarbazine, and corticosteroids (prednisone, methylprednisolone, dexamethasone).
During the study, patients will have blood tests every week. Complete exams will be given in Cycles 2 and 4; patients will return to the clinic for these. Every 2 or 3 cycles, patients will have a chest x-ray and CT scans of the abdomen and pelvis. Bone marrow samples will be taken. Heart function tests (EKG) will be done as needed.
After the study ends, patients will return for checkups every 3 months in the first year, every 4 months in years 2 and 3, and every 6 months in years 4 and 5. After that, checkups will be needed once a year. Blood and bone marrow samples will be taken at these visits.
This is an investigational study. Rituximab is approved by FDA for commercial use. The other drugs used in the study are also approved for commercial use. About 210 patients will take part in the study. All will be enrolled at University of Texas MD Anderson Cancer Center (UTMDACC).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: 1: FND + Rituximab Followed by Interferon Fludarabine/Novantrone/Decadron + Rituximab Followed by Interferon |
Drug: Fludarabine
Group 1= 25 mg/m^2 IV over 15 min. Days 2 through 4 for 8 Cycles; Group 2 = 25 mg/m^2 IV over 15 min. Days 1 through 3 for 8 Cycles.
Other Names:
Drug: Novantrone
Group 1 = 10 mg/m^2 IV over 15 min. Day 2 for 8 Cycles; Group 2 = 10 mg/m^2 IV over 15 min. Day 1 for 8 Cycles; Group 3 = 10 mg/m^2 IV over 15 min. Day 2 of 3rd Sequence.
Other Names:
Drug: Decadron
Group 1 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 2 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 3 = 40 mg PO Days 1 through 4 of 1st Sequence; After Completion of 3 Sequences, Days 1 through 3 Every Month for 1 Year.
Other Names:
Drug: Rituximab
Group 1 = 375 mg/m^2 IV Days 1 through 8 of Course 1, then Day 1 Only of Cycles 2 through 5; Group 2 = 4 Months after IFN Starts, 375 mg/m^2 IV Once Per Month for 6 Months; Group 3 = 375 mg/m^2 IV Days 1 through 8 of 1st Sequence; 375 mg/m^2 IV Days 1 through 8 of 3rd Sequence.
Other Names:
Drug: Interferon
Group 1 = After Completion of Fludarabine, Novantrone, & Rituximab, IFN 3 mcg/ml/m^2 SQ Days 1 through 14 Each Month for 1 year; Group 2 = After Completion of Fludarabine & Novantrone, IFN 3 mcg/ml/m^2 SQ Days 1 through 14 Each Month for 1 year; Group 3 = After Completion of 3 Sequences, IFN 3 mcg/ml/m^2 SQ Days 1 through 14 Each Month for 1 year.
Other Names:
|
| Active Comparator: 2: FND Followed by Interferon & Rituximab Fludarabine/Novantrone/Decadron Followed by Interferon & Rituximab |
Drug: Fludarabine
Group 1= 25 mg/m^2 IV over 15 min. Days 2 through 4 for 8 Cycles; Group 2 = 25 mg/m^2 IV over 15 min. Days 1 through 3 for 8 Cycles.
Other Names:
Drug: Novantrone
Group 1 = 10 mg/m^2 IV over 15 min. Day 2 for 8 Cycles; Group 2 = 10 mg/m^2 IV over 15 min. Day 1 for 8 Cycles; Group 3 = 10 mg/m^2 IV over 15 min. Day 2 of 3rd Sequence.
Other Names:
Drug: Decadron
Group 1 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 2 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 3 = 40 mg PO Days 1 through 4 of 1st Sequence; After Completion of 3 Sequences, Days 1 through 3 Every Month for 1 Year.
Other Names:
Drug: Rituximab
Group 1 = 375 mg/m^2 IV Days 1 through 8 of Course 1, then Day 1 Only of Cycles 2 through 5; Group 2 = 4 Months after IFN Starts, 375 mg/m^2 IV Once Per Month for 6 Months; Group 3 = 375 mg/m^2 IV Days 1 through 8 of 1st Sequence; 375 mg/m^2 IV Days 1 through 8 of 3rd Sequence.
Other Names:
Drug: Interferon
Group 1 = After Completion of Fludarabine, Novantrone, & Rituximab, IFN 3 mcg/ml/m^2 SQ Days 1 through 14 Each Month for 1 year; Group 2 = After Completion of Fludarabine & Novantrone, IFN 3 mcg/ml/m^2 SQ Days 1 through 14 Each Month for 1 year; Group 3 = After Completion of 3 Sequences, IFN 3 mcg/ml/m^2 SQ Days 1 through 14 Each Month for 1 year.
Other Names:
|
| Active Comparator: 3: CHOD-Bleo, ESHAP, NOPP + Rituximab Followed by Interferon Cyclophosphamide/Vincristine/Doxorubicin/Bleomycin (1st Sequence) + Rituximab; Etoposide/Cisplatin/Ara-C/Methyl-Prednisol (2nd Sequence); Novantrone/Vincristine/Procarbazine/Prednisone + Rituximab (3rd Sequence) Followed by Interferon |
Drug: Novantrone
Group 1 = 10 mg/m^2 IV over 15 min. Day 2 for 8 Cycles; Group 2 = 10 mg/m^2 IV over 15 min. Day 1 for 8 Cycles; Group 3 = 10 mg/m^2 IV over 15 min. Day 2 of 3rd Sequence.
Other Names:
Drug: Decadron
Group 1 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 2 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 3 = 40 mg PO Days 1 through 4 of 1st Sequence; After Completion of 3 Sequences, Days 1 through 3 Every Month for 1 Year.
Other Names:
Drug: Rituximab
Group 1 = 375 mg/m^2 IV Days 1 through 8 of Course 1, then Day 1 Only of Cycles 2 through 5; Group 2 = 4 Months after IFN Starts, 375 mg/m^2 IV Once Per Month for 6 Months; Group 3 = 375 mg/m^2 IV Days 1 through 8 of 1st Sequence; 375 mg/m^2 IV Days 1 through 8 of 3rd Sequence.
Other Names:
Drug: Interferon
Group 1 = After Completion of Fludarabine, Novantrone, & Rituximab, IFN 3 mcg/ml/m^2 SQ Days 1 through 14 Each Month for 1 year; Group 2 = After Completion of Fludarabine & Novantrone, IFN 3 mcg/ml/m^2 SQ Days 1 through 14 Each Month for 1 year; Group 3 = After Completion of 3 Sequences, IFN 3 mcg/ml/m^2 SQ Days 1 through 14 Each Month for 1 year.
Other Names:
Drug: Doxorubicin
25 mg/m^2 IV Days 2 & 3 of 1st Sequence.
Drug: Vincristine
.7 mg/m^2 IV Days 2 & 3 of 1st Sequence; 1.4 mg/m^2 IV Day 2 of 3rd Sequence.
Drug: Bleomycin
5 unit/m^2 IV Days 2 & 3 of 1st Sequence.
Drug: Cyclophosphamide
750 mg/m^2 IV Day 2 of 1st Sequence.
Drug: Etoposide
40 mg/m^2 IV Days 1 through 4 of 2nd Sequence.
Drug: Cisplatin
25 mg/m^2 IV Days 1 through 4 of 2nd Sequence
Drug: Ara-C
1.5 gm/m^2 IV Day 5 of 2nd Sequence.
Drug: Methyl-Prednisolone
500 mg IV Days 1 through 5 of 2nd Sequence.
Drug: Procarbazine
100 mg/m^2 PO Days 2 through 11 of 3rd Sequence.
Drug: Prednisone
100 mg PO Days 1 through 5 of 3rd Sequence.
|
Outcome Measures
Primary Outcome Measures
- Number of Participants With Overall Survival (10 Years) by Treatment [10 Years]
Overall Survival is the time from date of treatment start until date of death due to any cause or last Follow-up within 10 years.
Secondary Outcome Measures
- Number of Participants With Progression Free Survival (10 Years) by Treatment [10 years]
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Previously untreated stage IV indolent B-cell lymphoma [Amendment May 2001: eligibility restricted to follicular lymphoma]
-
Age <76
Exclusion Criteria:
N/A
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Texas MD Anderson Cancer Center | Houston | Texas | United States | 77030 |
Sponsors and Collaborators
- M.D. Anderson Cancer Center
- Genentech, Inc.
Investigators
- Principal Investigator: Nathan Fowler, MD, M.D. Anderson Cancer Center
Study Documents (Full-Text)
More Information
Additional Information:
Publications
None provided.- DM97-261
- NCI-2010-01566
Study Results
Participant Flow
| Recruitment Details | Recruitment period: March 1998 to May 2002 |
|---|---|
| Pre-assignment Detail | 35 participants without Bcl Gene rearrangement were not randomized to the study |
| Arm/Group Title | Fludarabine,Mitoxantrone, and Dexamethasone (FND)-Rituximab | Rituximab- Fludarabine,Mitoxantrone, and Dexamethasone (FND) | Patients Without Bcl Gene Rearrangement |
|---|---|---|---|
| Arm/Group Description | Fludarabine,Mitoxantrone, and Dexamethasone (FND) with follow-up Ritux,Flidara,Mitoxan,Dex | Fludarabine,Mitoxantrone, and Dexamethasone (FND) with concurrent Ritux,Flidara,Mitoxan,Dex. | ATT9 cycles; Rituximab 6 cycles |
| Period Title: Overall Study | |||
| STARTED | 85 | 90 | 35 |
| COMPLETED | 78 | 80 | 32 |
| NOT COMPLETED | 7 | 10 | 3 |
Baseline Characteristics
| Arm/Group Title | Fludarabine,Mitoxantrone, and Dexamethasone (FND)-Rituximab | Rituximab- Fludarabine,Mitoxantrone, and Dexamethasone (FND) | Patients w/o Bcl Gene Rearrangement | Total |
|---|---|---|---|---|
| Arm/Group Description | Fludarabine,Mitoxantrone, and Dexamethasone (FND) with follow-up Ritux,Flidara,Mitoxan,Dex | Fludarabine,Mitoxantrone, and Dexamethasone (FND) with concurrent Ritux,Flidara,Mitoxan,Dex. | ATT 9 cycles; Rituximab 6 cycles | Total of all reporting groups |
| Overall Participants | 78 | 80 | 35 | 193 |
| Age (years) [Mean (Full Range) ] | ||||
| Mean (Full Range) [years] |
52
|
54
|
51
|
52
|
| Sex: Female, Male (Count of Participants) | ||||
| Female |
51
65.4%
|
34
42.5%
|
18
51.4%
|
103
53.4%
|
| Male |
27
34.6%
|
46
57.5%
|
17
48.6%
|
90
46.6%
|
| Ethnicity (NIH/OMB) (Count of Participants) | ||||
| Hispanic or Latino |
4
5.1%
|
5
6.3%
|
4
11.4%
|
13
6.7%
|
| Not Hispanic or Latino |
67
85.9%
|
64
80%
|
27
77.1%
|
158
81.9%
|
| Unknown or Not Reported |
7
9%
|
11
13.8%
|
4
11.4%
|
22
11.4%
|
| Race (NIH/OMB) (Count of Participants) | ||||
| American Indian or Alaska Native |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Asian |
1
1.3%
|
1
1.3%
|
0
0%
|
2
1%
|
| Native Hawaiian or Other Pacific Islander |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Black or African American |
7
9%
|
1
1.3%
|
3
8.6%
|
11
5.7%
|
| White |
63
80.8%
|
67
83.8%
|
28
80%
|
158
81.9%
|
| More than one race |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Unknown or Not Reported |
7
9%
|
11
13.8%
|
4
11.4%
|
22
11.4%
|
| Region of Enrollment (participants) [Number] | ||||
| United States |
76
97.4%
|
77
96.3%
|
34
97.1%
|
187
96.9%
|
| United Arab Emirates |
0
0%
|
1
1.3%
|
0
0%
|
1
0.5%
|
| China |
0
0%
|
1
1.3%
|
1
2.9%
|
2
1%
|
| Panama |
0
0%
|
1
1.3%
|
0
0%
|
1
0.5%
|
| Malta |
1
1.3%
|
0
0%
|
0
0%
|
1
0.5%
|
| Mexico |
1
1.3%
|
0
0%
|
0
0%
|
1
0.5%
|
| Indolent Lymphoma Subtype (participants) [Number] | ||||
| FL |
56
71.8%
|
55
68.8%
|
111
317.1%
|
|
| MZL |
6
7.7%
|
12
15%
|
18
51.4%
|
|
| SLL |
16
20.5%
|
13
16.3%
|
29
82.9%
|
|
Outcome Measures
| Title | Number of Participants With Overall Survival (10 Years) by Treatment |
|---|---|
| Description | Overall Survival is the time from date of treatment start until date of death due to any cause or last Follow-up within 10 years. |
| Time Frame | 10 Years |
Outcome Measure Data
| Analysis Population Description |
|---|
| The outcome measures were only being analyzed for the two randomized arms Fludarabine,Mitoxantrone, and Dexamethasone (FND)-Rituximab and Rituximab- Fludarabine,Mitoxantrone, and Dexamethasone (FND) |
| Arm/Group Title | Fludarabine,Mitoxantrone, and Dexamethasone (FND)-Rituximab | Rituximab- Fludarabine,Mitoxantrone, and Dexamethasone (FND) |
|---|---|---|
| Arm/Group Description | Fludarabine,Mitoxantrone, and Dexamethasone (FND) with follow-up Ritux,Flidara,Mitoxan,Dex | Fludarabine,Mitoxantrone, and Dexamethasone (FND) with concurrent Ritux,Flidara,Mitoxan,Dex. |
| Measure Participants | 78 | 80 |
| Count of Participants [Participants] |
59
75.6%
|
58
72.5%
|
| Title | Number of Participants With Progression Free Survival (10 Years) by Treatment |
|---|---|
| Description | Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
| Time Frame | 10 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| The outcome measures were only being analyzed for the two randomized arms Fludarabine,Mitoxantrone, and Dexamethasone (FND)-Rituximab and Rituximab- Fludarabine,Mitoxantrone, and Dexamethasone (FND) |
| Arm/Group Title | Fludarabine,Mitoxantrone, and Dexamethasone (FND)-Rituximab | Rituximab- Fludarabine,Mitoxantrone, and Dexamethasone (FND) |
|---|---|---|
| Arm/Group Description | Fludarabine,Mitoxantrone, and Dexamethasone (FND) with follow-up Ritux,Flidara,Mitoxan,Dex | Fludarabine,Mitoxantrone, and Dexamethasone (FND) with concurrent Ritux,Flidara,Mitoxan,Dex. |
| Measure Participants | 78 | 80 |
| Count of Participants [Participants] |
59
75.6%
|
58
72.5%
|
Adverse Events
| Time Frame | 10 years | |||
|---|---|---|---|---|
| Adverse Event Reporting Description | Adverse events reported for the 2 randomized arms and not for the participants without bcl gene rearrangement. | |||
| Arm/Group Title | Fludarabine,Mitoxantrone, and Dexamethasone (FND)-Rituximab | Rituximab- Fludarabine,Mitoxantrone, and Dexamethasone (FND) | ||
| Arm/Group Description | Fludarabine,Mitoxantrone, and Dexamethasone (FND) with follow-up Ritux,Flidara,Mitoxan,Dex | Fludarabine,Mitoxantrone, and Dexamethasone (FND) with concurrent Ritux,Flidara,Mitoxan,Dex. | ||
All Cause Mortality |
||||
| Fludarabine,Mitoxantrone, and Dexamethasone (FND)-Rituximab | Rituximab- Fludarabine,Mitoxantrone, and Dexamethasone (FND) | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 19/78 (24.4%) | 22/80 (27.5%) | ||
Serious Adverse Events |
||||
| Fludarabine,Mitoxantrone, and Dexamethasone (FND)-Rituximab | Rituximab- Fludarabine,Mitoxantrone, and Dexamethasone (FND) | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 67/78 (85.9%) | 77/80 (96.3%) | ||
| Blood and lymphatic system disorders | ||||
| Neutropenic Fever | 2/78 (2.6%) | 4/80 (5%) | ||
| Neutropenia | 67/78 (85.9%) | 77/80 (96.3%) | ||
| Thrombocytopenia | 15/78 (19.2%) | 23/80 (28.8%) | ||
| Anemia | 10/78 (12.8%) | 11/80 (13.8%) | ||
| Gastrointestinal disorders | ||||
| Abdominal Pain | 1/78 (1.3%) | 1/80 (1.3%) | ||
| Nausea/Emesis | 4/78 (5.1%) | 4/80 (5%) | ||
| General disorders | ||||
| Fatigue | 15/78 (19.2%) | 12/80 (15%) | ||
| Fever | 1/78 (1.3%) | 3/80 (3.8%) | ||
| Infections and infestations | ||||
| Infection | 8/78 (10.3%) | 15/80 (18.8%) | ||
Other (Not Including Serious) Adverse Events |
||||
| Fludarabine,Mitoxantrone, and Dexamethasone (FND)-Rituximab | Rituximab- Fludarabine,Mitoxantrone, and Dexamethasone (FND) | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 67/78 (85.9%) | 77/80 (96.3%) | ||
| Blood and lymphatic system disorders | ||||
| Neutropenic Fever | 14/78 (17.9%) | 9/80 (11.3%) | ||
| Neutropenia | 67/78 (85.9%) | 13/80 (16.3%) | ||
| Thrombocytopenia | 15/78 (19.2%) | 14/80 (17.5%) | ||
| Anemia | 10/78 (12.8%) | 16/80 (20%) | ||
| Gastrointestinal disorders | ||||
| Abdominal Pain | 21/78 (26.9%) | 16/80 (20%) | ||
| Nausea / Emisis | 7/78 (9%) | 13/80 (16.3%) | ||
| General disorders | ||||
| Fatigue | 44/78 (56.4%) | 48/80 (60%) | ||
| Fever | 14/78 (17.9%) | 20/80 (25%) | ||
| Infections and infestations | ||||
| Infection | 17/78 (21.8%) | 18/80 (22.5%) | ||
| Nervous system disorders | ||||
| Neuropathy | 21/78 (26.9%) | 14/80 (17.5%) | ||
| Skin and subcutaneous tissue disorders | ||||
| Alopecia | 26/78 (33.3%) | 35/80 (43.8%) | ||
| Rash / Pruitius | 10/78 (12.8%) | 18/80 (22.5%) | ||
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Nathan Fowler,MD, Clinical Professor, Lymphoma-Myeloma |
|---|---|
| Organization | UT MD Anderson Cancer Center |
| Phone | (832) 671-3018 |
| nfowler@mdanderson.org |
- DM97-261
- NCI-2010-01566